Search

Displaying results 5811 - 5820 of 10000 in total
  1. Drug

    Tilarginine

    go.drugbank.com/drugs/DB11815
    ApprovedInvestigationalWithdrawn

    Tilarginine has been investigated for the basic science, treatment, and diagnostic of Obesity, Type 2 Diabetes, Ocular Physiology, and Regional Blood Flow.

  2. Drug

    Prifinium

    go.drugbank.com/drugs/DB13254
    Experimental

    It may be useful for the treatment of irritable bowel syndrome [A175027].

  3. Drug

    Guanosine-5'-Monophosphate

    go.drugbank.com/drugs/DB01972
    Experimental

    A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. [PubChem]

  4. Drug

    Digoxin Immune Fab (Ovine)

    go.drugbank.com/drugs/DB00076
    Approved

    Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.

  5. Drug

    ADU-S100

    go.drugbank.com/drugs/DB14722
    Investigational

    ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. … ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune

  6. Drug

    Olinciguat

    go.drugbank.com/drugs/DB15238
    Investigational

    Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

  7. Drug

    AV-COVID-19

    go.drugbank.com/drugs/DB15802
    Investigational

    The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine. … The vaccine is created from the receiving patients’ isolated peripheral blood monocytes.

  8. Drug

    MCC

    go.drugbank.com/drugs/DB05282
    Investigational

    MCC has been shown to have immune stimulatory and apoptosis (programmed cell death) activity against cancer cells. The product is a sterile biological composition in a sub-micron suspension. … It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec.

  9. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  10. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.